|By Marketwired .||
|April 22, 2014 02:00 AM EDT||
MANCHESTER, UNITED KINGDOM -- (Marketwired) -- 04/22/14 -- Epistem Holdings Plc (LSE:EHP)(AIM:EHP.L), Manchester, UK, the UK biotechnology and personalised medicine company, announce a further partnership with The University of Manchester to further the understanding of the biology of chronic delayed wound healing associated with skin ulcers.
The team, led by Dr Matthew Hardman have been awarded an MRC Industry Collaboration Agreement (MICA) grant from the UK Medical Research Council to help fund the investigations. Chronic delayed wound healing is most often found in the elderly and those with diabetes. Due to the increasingly aged population and rising incidence of diabetes the frequency of chronic wounds is increasing. However, there are very limited treatments available. The research, which investigates the role of specific inflammatory mediators produced by macrophages, is intended to lead to new preclinical models to evaluate potential new therapies in this area, as well as generate new therapeutic opportunities. Dr Hardman is a world-leading expert in the molecular and cellular aspects of pathological healing and heads a multi-disciplinary research group within the Manchester Healing Foundation Centre for Tissue Regeneration at the University. Epistem's Contract Research Services Division provides specialised preclinical and scientific research services to drug development and personal care companies in the areas of oncology, mucositis, inflammation (inflammatory bowel disease and rheumatoid arthritis), wound healing and skincare. Epistem are experienced in commercialising new technologies and the partnership will allow the Company to expand its existing range of wound healing models.
Dr Hardman, who is based in the University's Faculty of Life Sciences, said: "It is a real privilege to be awarded this collaborative grant sponsored by the Medical Research Council. This partnership represents a tremendous opportunity to realise the potential of our work."
Catherine Booth, Managing Director at Epistem, added: "We are delighted to be working with Dr Hardman again, who is a highly regarded wound healing expert, and to be able to provide our customers with access to cutting edge preclinical models."
Epistem will be giving two oral presentations on recent additions to its wound healing portfolio at The Symposium on Advanced Wound Care (SAWC) on Thursday 24th April.
Notes for editors
Epistem is a biotechnology and personalised medicine company commercialising its expertise in stem cells in the areas of epithelial (oncology, gastrointestinal and dermatological) and infectious diseases. Epistem develops innovative therapeutics, biomarkers and diagnostics (Genedrive®) alongside contract research services for drug development companies. The Group's core expertise is focused around the regulation of adult stem cells located in epithelial tissue including the gastrointestinal tract, skin, hair follicles, breast and prostate and utilizing novel, proprietary next generation molecular biology for use in personalised medicine.
Chief Executive Officer
+44 161 606 7258
Jul. 1, 2015 09:45 AM EDT Reads: 1,899
The most often asked question post-DevOps introduction is: “How do I get started?” There’s plenty of information on why DevOps is valid and important, but many managers still struggle with simple basics for how to initiate a DevOps program in their business. They struggle with issues related to current organizational inertia, the lack of experience on Continuous Integration/Delivery, understanding where DevOps will affect revenue and budget, etc. In their session at DevOps Summit, JP Morgenthal...
Jul. 1, 2015 09:32 AM EDT Reads: 128
Jul. 1, 2015 09:30 AM EDT Reads: 706
Jul. 1, 2015 09:15 AM EDT Reads: 2,097
Jul. 1, 2015 09:00 AM EDT Reads: 751
Jul. 1, 2015 08:00 AM EDT Reads: 758
Jun. 30, 2015 05:00 PM EDT Reads: 2,105
Jun. 30, 2015 03:59 PM EDT Reads: 627
Jun. 30, 2015 02:15 PM EDT Reads: 2,194
Jun. 30, 2015 01:45 PM EDT Reads: 2,031
Jun. 30, 2015 01:30 PM EDT Reads: 2,127
Jun. 30, 2015 12:30 PM EDT Reads: 1,858
Jun. 30, 2015 10:30 AM EDT Reads: 1,927
Jun. 30, 2015 10:20 AM EDT Reads: 584
Jun. 30, 2015 10:15 AM EDT Reads: 876